Skystar opens new R&D center

Chinese animal health company Skystar Bio-Pharmaceuticals has opened a new research and development center in Shanghai. The center, registered as Shanghai Siqiang Biotechnology, will employ six chief researchers, including four from the Chinese Academy of Agricultural Sciences. Staff will work on developing vaccines, treatments for parasitic disease and microorganism products including probiotics and antibiotics. Commenting on the new center, Skystar's CEO Weibing Lu said: "By locating our R&D center in Shanghai, the economic center of China, we believe the facility will attract high-level talent from all over the country, and serve as a base to cultivate future talent." jo.power@informa.com